相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
Huan Zhang et al.
CANCER GENE THERAPY (2022)
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
Dafne C. A. Quixabeira et al.
ONCOIMMUNOLOGY (2022)
Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report
Qi Zhao et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer
James H. A. Clubb et al.
FRONTIERS IN IMMUNOLOGY (2022)
CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
Roger Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer
Lili Huang et al.
CANCER MEDICINE (2022)
The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model
Moritz Klawitter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
Camilla Heinio et al.
DISEASES (2022)
Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion
Matthew Glen Robertson et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
Riikka Havunen et al.
CELLS (2021)
Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation
Marti Farrera-Sal et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
Bo-Kyeong Jung et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Development of MEM-288, a dual-transgene armed and conditionally replication-enhanced oncolytic adenovirus with potent systemic antitumor immunity
Hong Zheng et al.
CANCER RESEARCH (2020)
CD46 and Oncologic Interactions: Friendly Fire against Cancer
Michelle Elvington et al.
ANTIBODIES (2020)
The biology of the adenovirus E1B 55K protein
Paloma Hidalgo et al.
FEBS LETTERS (2019)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Frederick F. Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer
Matthew J. Atherton et al.
VACCINE (2018)
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng et al.
NATURE REVIEWS CANCER (2018)
Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
E. Eriksson et al.
GENE THERAPY (2017)
Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism
M. B. Garcia-Ortega et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2017)
The Adenovirus E1A C Terminus Suppresses a Delayed Antiviral Response and Modulates RAS Signaling
Nathan R. Zemke et al.
CELL HOST & MICROBE (2017)
Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1 MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.
Derek J. Jonker et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Emma Eriksson et al.
CLINICAL CANCER RESEARCH (2017)
The antitumor effects of oncolytic adenovirus H101 against lung cancer
Jie Lei et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma
Mikko Siurala et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Systematic Immunohistochemical Analysis of the Expression of CD46, CD55, and CD59 in Colon Cancer
Yulong Shang et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
The impact of PKR activation: from neurodegeneration to cancer
Juan A. Marchal et al.
FASEB JOURNAL (2014)
ORCA-010, a Novel Potency-Enhanced Oncolytic Adenovirus, Exerts Strong Antitumor Activity in Preclinical Models
Wenliang Dong et al.
HUMAN GENE THERAPY (2014)
Adenovirus E1B 19-Kilodalton Protein Modulates Innate Immunity through Apoptotic Mimicry
Jay R. Radke et al.
JOURNAL OF VIROLOGY (2014)
Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model
Yang Yan et al.
TUMOR BIOLOGY (2014)
Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis
M. Reeh et al.
BRITISH JOURNAL OF CANCER (2013)
PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis
X. Cheng et al.
BLOOD CANCER JOURNAL (2013)
Viral Retasking of hBre1/RNF20 to Recruit hPaf1 for Transcriptional Activation
Gregory J. Fonseca et al.
PLOS PATHOGENS (2013)
Adenovirus Evasion of Interferon-Mediated Innate Immunity by Direct Antagonism of a Cellular Histone Posttranslational Modification
G. J. Fonseca et al.
CELL HOST & MICROBE (2012)
A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression
Yasumoto Yamasaki et al.
EUROPEAN JOURNAL OF CANCER (2012)
A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
James M. Burke et al.
JOURNAL OF UROLOGY (2012)
Avidity Binding of Human Adenovirus Serotypes 3 and 7 to the Membrane Cofactor CD46 Triggers Infection
Hung V. Trinh et al.
JOURNAL OF VIROLOGY (2012)
Impact of the coxsackievirus and adenovirus receptor on the adenoma-carcinoma sequence of colon cancer
K. Stecker et al.
BRITISH JOURNAL OF CANCER (2011)
Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b
F. Hedjran et al.
CANCER GENE THERAPY (2011)
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
Hongjie Wang et al.
NATURE MEDICINE (2011)
Adenovirus E1A interacts directly with, and regulates the level of expression of, the immunoproteasome component MECL1
Sarah Berhane et al.
VIROLOGY (2011)
Adenovirus Vector-Derived VA-RNA-Mediated Innate Immune Responses
Mitsuhiro Machitani et al.
Pharmaceutics (2011)
In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy
Julia Davydova et al.
CANCER SCIENCE (2010)
Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
Anniina Koski et al.
MOLECULAR THERAPY (2010)
Induction of type I interferon by adenovirus-encoded small RNAs
Tomoko Yamaguchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
T. Christopher Mast et al.
VACCINE (2010)
Predictive modeling in cancer: where systems biology meets the stock market
Maysam F. Abbod et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo
Nian-Hua Zhang et al.
CELL CYCLE (2008)
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
Irene Kuhn et al.
PLOS ONE (2008)
Homo- and heterotypic cell contacts in malignant melanoma cells and desmoglein 2 as a novel solitary surface glycoprotein
Christian J. Schmitt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma
Ilya V. Ulasov et al.
HUMAN GENE THERAPY (2007)
Adenovirus type 11 binding alters the conformation of its receptor CD46
B. David Persson et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation
W. M. Korn et al.
CANCER GENE THERAPY (2006)
Adenovirus virus-associated RNA is processed to functional interfering RNAs involved in virus production
O Aparicio et al.
JOURNAL OF VIROLOGY (2006)
Induction of interferon synthesis by the PKR-inhibitory VA RNAs of adenoviruses
F Weber et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2006)
Expression of double-stranded RNA-activated protein kinase in small-size peripheral adenocarcinoma of the lung
MS Roh et al.
PATHOLOGY INTERNATIONAL (2005)
Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer
K Biedermann et al.
JOURNAL OF PATHOLOGY (2005)
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
CC O'Shea et al.
CANCER CELL (2004)
Telomerase-specific replication-selective virotherapy for human cancer
T Kawashima et al.
CLINICAL CANCER RESEARCH (2004)
Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells
M Nilsson et al.
JOURNAL OF GENE MEDICINE (2004)
Functions and mechanisms of action of the adenovirus E3 proteins
DL Lichtenstein et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2004)
Adenovirus type 11 uses CD46 as a cellular receptor
A Segerman et al.
JOURNAL OF VIROLOGY (2003)
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus
A Kanerva et al.
MOLECULAR THERAPY (2003)
An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression
M Campbell et al.
CANCER GENE THERAPY (2003)
The adenovirus E3 RID complex protects some cultured human T and B lymphocytes from Fas-induced apoptosis
AL McNees et al.
JOURNAL OF VIROLOGY (2002)
Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency
HJ Wu et al.
HUMAN GENE THERAPY (2002)
Adenovirus E3-6.7K maintains calcium homeostasis and prevents apoptosis and arachidonic acid release
AR Moise et al.
JOURNAL OF VIROLOGY (2002)
Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins
AE Tollefson et al.
JOURNAL OF VIROLOGY (2001)
Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?
BR Dix et al.
JOURNAL OF VIROLOGY (2001)
Membrane cofactor protein (MCP; CD46) expression in transgenic mice
C Kemper et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2001)
Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and-2
CA Benedict et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Protein expression of double-stranded RNA-activated protein kinase (PKR) in intrahepatic bile ducts in normal adult livers, fetal livers, primary biliary cirrhosis, hepatolithiasis and intrahepatic cholangiocarcinoma
W Terada et al.
LIVER (2000)
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
J Fueyo et al.
ONCOGENE (2000)
Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells
VI Rebel et al.
STEM CELLS (2000)
分享论文
